Illumina and Kindstar Global Announce Strategic Collaboration to Facilitate Clinical Adoption of Illumina Technologies in Asia

  Illumina and Kindstar Global Announce Strategic Collaboration to Facilitate
  Clinical Adoption of Illumina Technologies in Asia

Business Wire

SAN DIEGO & WUHAN, China -- April 18, 2013

Illumina, Inc. (NASDAQ: ILMN) and Kindstar Global (Kindstar) today announced
they are entering into a strategic collaboration whereby Kindstar will
validate and implement molecular assays in their laboratories, leveraging
Illumina’s TruSight^TM content sets, Infinium® Dx CytoSNP-12 assay and
NuPCR^TM reagents. The collaboration will enable Kindstar to expand its
esoteric and specialty testing services offerings within its network of more
than 3,300 hospitals across China.

“Kindstar’s adoption of Illumina’s TruSight technology across its extensive
network in China speaks to the breadth and depth of content in this innovative
portfolio,” said Matt Posard, Senior Vice President and General Manager of
Illumina’s Translational and Consumer Genomics business. “Next-generation
sequencing is enabling a dramatic improvement in both coverage and accuracy
for molecular diagnostics, and we look forward to additional partnerships that
continue to drive this improvement forward.”

“Kindstar is excited to offer services in China based on Illumina’s products
including the TruSight content sets,” said Dr. Shiang Huang, Founder and CEO
of Kindstar. “Leveraging Illumina’s technology will enable us to offer the
highest quality and most specialized diagnostics.”

About Illumina

Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer
of life science tools and integrated systems for the analysis of genetic
variation and function. We provide innovative sequencing and array-based
solutions for genotyping, copy number variation analysis, methylation studies,
gene expression profiling, and low-multiplex analysis of DNA, RNA, and
protein. We also provide tools and services that are fueling advances in
consumer genomics and diagnostics. Our technology and products accelerate
genetic analysis research and its application, paving the way for molecular
medicine and ultimately transforming healthcare.

About Kindstar Global

Kindstar Global, with laboratory facilities inBeijing,ShanghaiandWuhan,
provides esoteric diagnostic testing services to hospitals and physicians in
every province ofChina. Kindstar is the first and largest esoteric diagnostic
testing business inChina, providing laboratory testing services to over 3,300
Chinese hospitals, including 930 tertiary hospitals (classification for
largest leading hospitals). Kindstar is becoming the partner of choice to
physicians inChinafor advanced diagnostics in many medical specialties
including hematology, oncology, infectious diseases and medical genetics.

Forward-Looking Statements

This release may contain forward looking statements that involve risks and
uncertainties. Important factors that could cause actual results to differ
materially from those in any forward-looking statements are detailed in our
filings with the Securities and Exchange Commission, including our most recent
filings on Forms 10-K and 10-Q, or in information disclosed in public
conference calls, the date and time of which are released beforehand. We do
not intend to update any forward-looking statements after the date of this
release.

Contact:

Illumina Inc.
Investors:
Rebecca Chambers
858-255-5243
rchambers@illumina.com
or
Media:
Jennifer Temple
858-882-6822
pr@illumina.com